Tumor necrosis factor inhibitors may result in weight gain in Psoriasis patients

In a study published in the Journal of the American Academy of Dermatology, the use of tumor necrosis factor inhibitors was associated with an increase in body weight and body mass index. Consideration for other treatments should be considered for patients who are overweight or obese.

Commonly used tumor necrosis factor inhibitors:

  • Adalimumab (Humira®)
  • Certolizumab pegol (Cimzia®)
  • Etanercept (Enbrel®)
  • Golimumab (Simponi®, Simponi Aria®)
  • Infliximab (Remicade®)

 

Obesity and Type II Diabetes linked to Psoriasis

In a study published in JAMA, persons with Type II diabetes or obesity were at significantly increased risk of developing  psoriasis.

Obesity is a significant risk factor for type II diabetes as well.

Therefore, eating a good healthy diet that is low in saturated fats and simple carbohydrates, exercising regularly, and maintaining an ideal weight is beneficial  to one’s skin.